Futura Medical plc (LSE:FUM) has appointed an interim Chief Financial Officer as its Finance Director and Chief Operating Officer prepares to step down. The AIM-quoted consumer healthcare group also said its formal sale process has moved on, with a detailed information memorandum now being circulated to interested parties.

What was announced

In an announcement dated 8 October 2026, Futura Medical (LSE:FUM) said Angela Hildreth will step down as Finance Director and Chief Operating Officer to pursue other opportunities. Her departure from the executive role takes effect on 13 November 2026, following what the company described as an orderly handover. She will remain on the Board as a Non-Executive Director for the duration of the M&A Process and Formal Sale Process (FSP), so that the company keeps access to her knowledge of the Business while those processes continue.

Madelein "Maddy" Kennedy has been appointed Interim Chief Financial Officer from 12 October 2026. She will serve on a consultancy basis through MadJak Associates Limited, which trades as CFO4Growth. Separately, the company has appointed ESGovernance Ltd to provide outsourced company secretarial and governance support.

The incoming interim CFO

According to the announcement, Ms Kennedy has more than 30 years of finance experience, including senior roles in life sciences, healthcare and AIM-quoted companies. Since 2010 she has provided fractional CFO support to small and medium-sized life science and technology businesses. She was previously Chief Financial Officer of Lab21 Limited and Finance Director of AIM-listed Alliance Pharma plc. She currently serves as a Non-Executive Director and Audit Committee member of AIM-listed Nuformix plc, and as a Non-Executive Director of Heartbeat Care CIC.

Chair Andrew Unitt thanked Ms Hildreth for her contribution to the company and said Ms Kennedy brings "substantial life sciences, AIM and transaction experience". The Board said it remains focused on progressing the M&A Process and FSP in order to preserve and realise value for shareholders. The fees and expected duration of the interim appointment were not disclosed.

Where the sale process stands

Futura first announced the M&A Process and Formal Sale Process on 3 September 2026. At that stage, interested parties had been invited to submit non-binding offers by 2 October 2026. The company said it has received positive interest since the September announcement and has now begun circulating a detailed information memorandum to interested parties.

As a result, the Board now expects non-binding offers to be invited over approximately the next four weeks, subject to progress in the process. The timetable has therefore moved on from the original 2 October date. The company did not disclose how many parties have expressed interest or received the memorandum.

Futura stressed that there can be no certainty that any offer will be made, that any transaction will be concluded, or as to the terms of any such offer. No firm offer and no possible offer from a named party has been announced. Present Value Ltd is acting exclusively for Futura on the M&A Process and FSP. Panmure Liberum is the company's Nominated Adviser and Joint Broker, and Turner Pope Investments is Joint Broker. The announcement also carries standard Takeover Code disclosure notices for holders of interests of 1% or more in the company's securities.

Background and what to watch next

Futura describes itself as a consumer healthcare group focused on developing and commercialising clinically proven sexual health products. Its lead product is Eroxon, a topical gel for erectile dysfunction that the company describes as the only over-the-counter topical gel for the condition, with licence and distribution partnerships across major consumer markets. Its development pipeline includes Eroxon Intense and WSD4000, a female sexual health portfolio beginning with topical gels.

Points to watch include the formal handover between Ms Hildreth and Ms Kennedy ahead of 13 November, and any further update on the invitation and receipt of non-binding offers over the coming weeks. Any approach would fall to be disclosed under the Takeover Code.